World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
81
Citations
23847
World Ranking
16661
National Ranking
666

Bruno Vincenzi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Bruno Vincenzi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 838 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Bruno Vincenzi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Bruno Vincenzi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 81 D-Index — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Bruno Vincenzi is affiliated with Università Campus Bio-Medico in Italy, focusing primarily on medical research with a substantial publication record in the field of medicine. Their work spans several prominent subfields including pulmonary and respiratory medicine, oncology, surgery, rheumatology, and molecular biology.

The research topics they frequently address include sarcoma diagnosis and treatment, cardiac tumors and thrombi, lung cancer treatments and mutations, cancer immunotherapy and biomarkers, gastrointestinal tumor research and treatment, COVID-19 and its impacts on healthcare, as well as vascular tumors and angiosarcomas.

Vincenzi has contributed to multiple papers published in well-regarded venues. Some of the notable recent papers include:

  • "Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples," 2020, Journal of Experimental & Clinical Cancer Research
  • "Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors," 2023, New England Journal of Medicine
  • "Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer," 2020, Cancer Discovery
  • "Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study," 2021, The Lancet Oncology
  • "Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group," 2020, Cancer

The scientist has published extensively in several key journals, with frequent appearances in:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • ESMO Open
  • Cancers
  • Precision Cancer Medicine

Collaborations are a notable aspect of Vincenzi's career. Common coauthors include Giuseppe Tonini, Daniele Santini, Alessio Cortellini, Giovanni Grignani, and Francesco Pantano, reflecting an active network of collaboration in oncological and medical research.

Overall, their body of work underscores an engagement with complex clinical and molecular challenges in cancer treatment and diagnosis, as well as investigations into the impacts of COVID-19 on cancer patients and treatment outcomes.

Best Publications

  • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter

  • KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

    F Loupakis;A Ruzzo;C Cremolini;B Vincenzi

  • Zoledronic Acid Induces Significant and Long-Lasting Modifications of Circulating Angiogenic Factors in Cancer Patients

    Daniele Santini;Bruno Vincenzi;Giordano Dicuonzo;Giuseppe Avvisati

  • Pamidronate Induces Modifications of Circulating Angiogenetic Factors in Cancer Patients

    Daniele Santini;Bruno Vincenzi;Giuseppe Avvisati;Giordano Dicuonzo

  • Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients

    Cristina Raimondi;Angela Gradilone;Giuseppe Naso;Bruno Vincenzi

  • High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.

    Daniele Santini;Fotios Loupakis;Bruno Vincenzi;Irene Floriani

  • Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.

    T C Mineo;V Ambrogi;A Baldi;C Rabitti

  • Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

    D. Santini;B. Vincenzi;R. Addeo;C. Garufi

  • Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients

    Daniele Santini;Bruno Vincenzi;Sara Galluzzo;Fabrizio Battistoni

  • Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib

    Bruno Vincenzi;Daniele Santini;Antonio Russo;Raffaele Addeo

  • The antineoplastic role of bisphosphonates: from basic research to clinical evidence

    D. Santini;U. Vespasiani Gentilucci;B. Vincenzi;A. Picardi

  • Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?

    Giuseppe Badalamenti;Daniele Fanale;Lorena Incorvaia;Nadia Barraco

  • Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

    Marco Russano;Andrea Napolitano;Giulia Ribelli;Michele Iuliani

  • Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients.

    Daniele Santini;Gaia Schiavon;Gaia Schiavon;Bruno Vincenzi;Laura Maria Gaeta

  • Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients

    D. J. Pinato;A. Zambelli;A. Bertuzzi;A. Marrari

  • Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients.

    Bruno Vincenzi;Daniele Santini;Giordano Dicuonzo;Fabrizio Battistoni

  • Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance

    Raffaele Addeo;Michele Caraglia;Sergio Bellini;Alberto Abbruzzese

  • Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study

    Paola Sperone;Anna Ferrero;Fulvia Daffara;Adriano Priola

  • Pamidronate (P) induces modifications of circulating angiogenetic factors in cancer patients

    D. Santini;B. Vincenzi;G. Di Cuonzo;F. Battistoni

  • KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

    A. Ruzzo;F. Loupakis;E. Canestrari;Chiara Cremolini

Frequent Co-Authors

Daniele Santini
Daniele Santini Università Campus Bio-Medico
Giuseppe Tonini
Giuseppe Tonini Università Campus Bio-Medico
Alfonso Baldi
Alfonso Baldi University of Campania "Luigi Vanvitelli"
Antonio Russo
Antonio Russo University of Palermo
Alfredo Falcone
Alfredo Falcone University of Pisa
Michele Caraglia
Michele Caraglia University of Campania "Luigi Vanvitelli"
Fotios Loupakis
Fotios Loupakis Istituto Oncologico Veneto
Paolo G. Casali
Paolo G. Casali University of Milan
Angelo Paolo Dei Tos
Angelo Paolo Dei Tos University of Padua
Silvia Stacchiotti
Silvia Stacchiotti University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a traditional medical education in the USA is demanding—and often costly. However, there are alternative online degrees and career pathways in the health sector that offer flexibility and affordability for aspiring healthcare professionals.

For those interested in health information systems, earning a him associate degree online can open doors to administrative and data roles within the healthcare industry. Another in-demand option is medical billing and coding. Prospective students often want to know how much is medical billing and coding school, and many affordable online programs exist that prepare students for certification and entry-level careers.

Nursing continues to be a popular choice. You can find the cheapest np programs online to advance from registered nurse to nurse practitioner. For those starting out, exploring the cheapest bsn programs online is a cost-effective way to earn a Bachelor of Science in Nursing.

These alternative online pathways offer varied routes into healthcare—making a fulfilling career more accessible, regardless of your starting point.

Best Scientists Citing Bruno Vincenzi

Trending Scientists

Recently Published Articles